-The Times of India The report of the comptroller and auditor general (CAG) on the Delhi government for the year ended March 2012 is a scathing indictment of many departments and public utilities. Healthcare, transport, power, water and sewage and even showcase infrastructure projects and schemes have been put under the lens and the picture that has emerged is not all that pretty. The report was tabled in the Delhi assembly...

-The Times of India KOLKATA: A 22-year-old post graduate student and leader of CPM's students' wing SFI, died of injuries sustained in police custody, prompting the Left Front to demand a judicial probe on Tuesday while chief minister Mamata Banerjee and her senior cabinet colleagues attended the IPL inauguration ceremony barely a few km away. Police claimed SFI state committee member Sudipto Gupta's death was an accident while the victim's kin alleged...

-The Business Standard Interview with Founder chairman of Cancer Patients Aid Association Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting. Sapru, founder chairman of Cancer Patients Aid Association, or CPAA (which moved the Supreme Court to keep the prices of the cancer drug low), tells Sushmi Dey what the judgment means to cancer patients....

-The Hindu Considering the knowledge of English as a mark of social advancement and that of the vernacular as backwardness disenfranchises significant sections of society In a village in Ghazipur district that borders Varanasi, there is a young man who teaches English and "personality development" to the sons and daughters of local shopkeepers, farmers and truck drivers. The classes are held from 6 to 8 in the morning and again in the...

-The Economic Times Should drug companies make clinical trials data public? All over the world, drug regulators are increasingly in favour of doing so, much to the discomfort of pharmaceutical companies, and the London-based European Medicines Agency (EMA) is the first mover in this regard. As the journal Nature reports, EMA is likely to do so by next year, at least for some clinical trials data. On April 19, all the...